Utility of the RIG-I agonist triphosphate RNA for melanoma therapy

The pattern-recognition receptor RIG-I plays an important role in the recognition of non-self RNA and antiviral immunity. RIG-I9s natural ligand, triphosphate RNA (ppp-RNA), is proposed to be a valuable addition to the growing arsenal of cancer immunotherapy treatment options. In this study we present comprehensive data validating the concept and utility of treatment with synthetic RIG-I agonist ppp-RNA for the therapy of human cancer, with melanoma as potential entry indication amenable to intratumoral treatment. Using mRNA expression data of human tumors, we demonstrate that RIG-I expression is closely correlated to cellular and cytokine immune activation in a wide variety of tumor types. Furthermore, we confirm susceptibility of cancer cells to ppp-RNA treatment in different cellular models of human melanoma, revealing unexpected heterogeneity between cell lines in their susceptibility to RNA agonist features, including sequence, secondary structures and presence of triphosphate. Cellular responses to RNA treatment (induction of type I IFN, FasR, MHC-I and cytotoxicity) were demonstrated to be RIG-I dependent using KO cells. Following ppp-RNA treatment of a mouse melanoma model, we observed significant local and systemic anti-tumor effects and survival benefits. These were associated with type I IFN response, tumor cell apoptosis and innate and adaptive immune cell activation. For the first time, we demonstrate systemic presence of tumor antigen specific CTLs following treatment with RIG-I agonist. Despite potential challenges in the generation and formulation of potent RIG-I agonists, ppp-RNA or analogs thereof have potential to play an important role for cancer treatment in the next wave of immunotherapy.